Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?

Jin Park¹, Sung Hee Lim¹, Se Hyung Kim¹, Jina Yun¹, Chan Kyu Kim¹, Sang Cheol Lee², Jong Ho Won³, Dae Sik Hong¹, and Seong Kyu Park¹

¹Division of Hemato-oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon; ²Division of Hemato-oncology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan; ³Division of Hemato-oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea

Received: November 21, 2018
Revised: March 11, 2019
Accepted: March 23, 2019

Correspondence to Seong Kyu Park, M.D.
Division of Hemato-oncology, Department of Internal Medicine, Soonchunhyang University Bucheon, Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea
Tel: +82-32-621-5185
Fax: +82-32-621-5018
E-mail: skpark@schmc.ac.kr

Background/Aims: Immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT) is affected by multiple variables during the transplantation.

Methods: We assessed the clinical factors contributing to immune function reconstitution at 100 days post-allogeneic HSCT in 114 patients receiving fludarabine-based conditioning. Immunophenotypic analysis using flow cytometry was performed to evaluate the percentage and the absolute numbers of T-cell subsets, natural killer cells, and B-cells as clinical outcomes.

Results: Tacrolimus-based graft-versus-host disease (GVHD) prophylaxis, T-cell depletion, and acute GVHD were significantly associated with delayed immune reconstitution of T-cell subsets. The incidence of chronic GVHD was significantly increased in the normal recovery group compared to the abnormal group (p = 0.01). Epstein-Barr virus reactivation was more frequently observed in the abnormal group of T-cell subsets (p = 0.045). All viral reactivation events including cytomegalovirus reactivation appeared to be more frequent in the abnormal group of T-cell subsets.

Conclusions: The immune recovery status post-allogeneic HSCT was affected by GVHD prophylactic regimens, especially in cases receiving tacrolimus-based GVHD prophylaxis, T-cell depletion, and possibly those manifesting acute GVHD. Delayed immune reconstitution might increase the morbidity due to viral reactivation. Treatment strategies are needed to prevent infectious complications and enhance immune reconstitution based on the immune recovery status following allogeneic HSCT with fludarabine-based conditioning.

Keywords: Hematopoietic stem cell transplantation; Immunity; Treatment outcomes; Graft vs host disease

INTRODUCTION

Immune recovery after allogeneic hematopoietic stem cell transplantation (HSCT) depends on several variables during the transplantation including the specific conditioning regimens, types of donor, source of hematopoietic progenitor cells, and approaches to prevent graft-versus-host disease (GVHD) [1]. For example, T-cell depletion is used to decrease the frequency of GVHD. T-cell depletion of the allograft leads to significantly delayed immune reconstitution and increases morbidity and mortality due to infection in both younger and older recipients [1,2]. In patients with GVHD, immune reconstitution and response to vaccines is further hin-
dered by the use of systemic corticosteroids and other immunosuppressive drugs to treat chronic GVHD [3]. In addition, thymus is extremely sensitive to immunosuppressive treatments for GVHD prophylaxis, and GVHD itself [4].

Reconstitution of the immune system following allogeneic HSCT is a complex process that requires successful engraftment of hematopoietic stem cells, as well as adequate thymic function. Recovery of innate and adaptive immune systems occurs gradually during the post-transplantation period. Innate immunity usually recovers during the initial several months, whereas reconstitution of adaptive immunity occurs over the first 1 to 2 years. Delay in immune system recovery is associated with morbidity and mortality [5].

For patients who undergo stem cell transplantation, day 100 following the procedure is an important milestone. The risk of transplant-related complications and infections is the highest during the first 100 days post-transplantation. Immune recovery after allogeneic HSCT is characterized by cellular immune deficiencies involving a reduced number of cytotoxic lymphocytes, natural killer (NK) cells in the innate immune system, and T-cells in the specific immune system [5].

In this study, we assessed the clinical factors including the GVHD prophylactic regimens that affect the immune recovery status at 100 days after allogeneic HSCT in patients who receive fludarabine-based conditioning. In addition, the effect of immune reconstitution on clinical outcomes including the overall survival, disease-free survival, non-relapse mortality, and relapse rate was evaluated.

METHODS

Ethical statement
This study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital (2015-07-029) with written informed consents.

Patients
One hundred fourteen patients were included in this retrospective analysis. The patients received allogeneic HSCT at Soonchunhyang University Bucheon Hospital from August 2004 to April 2016. The diagnoses included acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), lymphoma, multiple myeloma, chronic myelogenous leukemia (CML), and aplastic anemia. The pre-transplantation status of acute leukemia patients varied and included first complete remission (CR1), second complete remission (CR2), third complete remission (CR3), and refractory status. To calculate hematopoietic cell transplantation-comorbidity index (HCT-CI), baseline studies were conducted that included echocardiography and pulmonary function tests. Based on the risk stratification using HCT-CI scores [6], patients were categorized into two risk groups. The standard-risk group showed low or intermediate risk, and the high-risk group had high risk. Several conditioning regimens with various dose intensities were administered according to disease type, disease status at the time of transplant, and HCT-CI scores. The myeloablative conditioning regimens included busulfan (12.8 mg/kg)/fludarabine (150 to 160 mg/m²) with or without antithymocyte globulin. The reduced intensity conditioning regimen included busulfan (6.4 to 9.6 mg/kg)/fludarabine (150 to 180 mg/m²) with or without antithymocyte globulin (thymoglobulin, 5 to 9 mg/kg in 3 days) or alemtuzumab (30 mg/day for 2 days). The combination of fludarabine (150 mg/m²)/cyclophosphamide (120 mg/kg)/antithymocyte globulin was used as a conditioning regimen for patients with aplastic anemia. Patients received peripheral blood stem cells from matched sibling donors, matched unrelated donors, or haplo-identical related donors. Patients received calcineurin inhibitor-based GVHD prophylaxis (cyclosporine-A or tacrolimus).

Evaluation of the immune status post-transplantation
For the identification and enumeration of different subpopulations of peripheral blood lymphocytes, immunophenotypic analysis using flow cytometry was performed at 100 days after the transplant. To determine the T-cell status, the percentage and the absolute numbers of CD3+, CD4+, and CD8+ cells per microliter of blood were evaluated. Absolute counts were calculated based on the proportion of these cells in the lymphocyte gate, percentage of lymphocytes, and complete blood counts. The CD16+CD56+ cell numbers and percentages were determined to measure NK cells. To evaluate the B-cell status, we evaluated the percentage and the
absolute counts of CD19+ B-cells and the serum levels of immunoglobulin (Ig) including IgG, IgM, and IgA. The lymphocyte reference ranges [7] were 801 to 2,534/μL for CD3+ cells, 482 to 1,620/μL for CD4+ cells, 341 to 1,352/μL for CD8+ cells, 62 to 1,278/μL for CD16+CD56+ NK cells, and 71 to 830/μL for CD19+ B-cells. The reference ranges of serum immunoglobulin were 408 to 1,788 mg/dL for IgG, 70 to 400 mg/dL for IgA, and 40 to 230 mg/dL for IgM.

Statistical analyses
The primary endpoint was the impact of clinical factors including GVHD prophylactic regimen in immune recovery of patients undergoing allogeneic HSCT. The secondary endpoints included the correlation between the immune recovery status and clinical outcomes. The clinical outcomes were disease-free survival (DFS), overall survival (OS), acute and chronic GVHD, non-relapse mortality (NRM), and relapse. All outcomes were measured from the time of stem cell infusion. The DFS was defined as survival without leukemia progression or relapse. Patients alive without disease progression or relapse were censored at the time of last contact. The OS was based on death from any cause. Surviving patients were censored at the time of last contact. Relapse was defined as the time to onset of hematologic recurrence or disease progression. Genetic relapse was assessed by the decrease in the rate of donor chimerism status below 95% or the reappearance of tumor target gene markers. NRM was defined as death from any cause without relapse in continuous complete remission or without progression. The incidence of grade II to IV or III to IV acute and chronic or extensive chronic GVHD was based on classical criteria [8,9].

The patients were categorized into two groups according to the immune recovery status 100 days after allogeneic HSCT. Based on quantitative analysis of peripheral lymphocytes via flow cytometry, the normal group was defined by T-cell subsets, B-cells, or serum immunoglobulins within their reference ranges, and the abnormal group was defined by levels outside the reference ranges.

Statistical differences in demographic and clinical characteristics between the normal and abnormal groups were evaluated using chi-square or Fisher’s exact test for categorical variables, and Student’s t test or Wilcoxon’s rank sum test for continuous variables. The Mann-Whitney U test was used to determine the statistical validity of non-parametric statistics depending on whether the intensive tendencies of two independent variables varied in the non-even distribution group. Probabilities of OS and DFS were estimated using Kaplan-Meier survival curves. Log-rank test was used to compare survival curves. A univariate Cox proportional hazards regression analysis was performed to correlate clinical variables with immune recovery. Based on the results of univariate Cox proportional hazard regression analysis, significant variables were selected for multivariate Cox proportional hazards regression analysis.

A p value of 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 14.0 KO version for Windows (SPSS Inc., Chicago, IL, USA) and a freely available R 3.1.3 version (http://cran.r-project.org/).

RESULTS

Patients’ demographic and clinical characteristics
The study included a total of 114 patients. The demographic and clinical data are presented in Table 1. The median follow-up of the survivors was 43 months (range, 6 to 113). The median age at baseline was 43.5 years (range, 2 to 71). Sixty-two patients (54.4%) were male. Transplants were performed in 35 patients (30.7%) from 2004 to 2008, in 47 patients (40.2%) from 2009 to 2014, and in 32 patients (28.1%) from 2015 to 2017. Among the 114 patients, the most common type of disease was AML (n = 59, 51.8%) followed by ALL (n = 27, 23.7%). Eleven MDS patients and four lymphoma patients were included. Among the 11 MDS patients, six carried a lower risk, and five had a higher risk based on International Prognostic Scoring System of MDS at the time of diagnosis. Four lymphoma patients showing partial response to chemotherapy received HSCT. Other cases included multiple myeloma (n = 4), chronic myeloid leukemia in blast crisis (n = 3), severe aplastic anemia (n = 3), chronic lymphocytic leukemia (n = 2), and primary myelofibrosis (n = 1). We could not classify cytogenetic risk based on cytogenetic and molecular findings at diagnosis because of insufficient information available and changing criteria for risk stratification with time. Myeloablative conditioning
Table 1. Demographic and clinical characteristics (n = 114)

| Variable          | Value        |
|-------------------|--------------|
| Age, yr           | 43.5 (2–71)  |
| < 40              | 48 (42.1)    |
| 40–49             | 28 (24.6)    |
| 50–59             | 29 (25.4)    |
| ≥ 60              | 9 (7.9)      |
| Sex               |              |
| Male              | 62 (54.4)    |
| Female            | 52 (45.6)    |
| Diagnosis         |              |
| AML               | 59 (51.8)    |
| ALL               | 27 (23.7)    |
| MDS               | 11 (9.6)     |
| Lymphoma          | 4 (3.5)      |
| Others            | 13 (11.4)    |
| Cytogenetics      |              |
| Normal            | 64 (56.1)    |
| Abnormal          | 50 (43.9)    |
| Risk stratification by HCT-CI | |
| Standard          | 66 (57.9)    |
| High              | 48 (42.1)    |
| Disease status at HSCT<sup>a</sup> | |
| CR                | 73 (64.1)    |
| Non-CR            | 25 (21.9)    |
| Others            | 16 (14.0)    |
| Conditioning regimen |          |
| Myeloablative     | 82 (71.9)    |
| Reduced intensity/non-myeloablative | 32 (28.1) |
| Type of allogeneic HSCT | |
| Matched related donor | 30 (26.3) |
| Matched unrelated donor | 68 (59.7) |
| Haploidentical donor | 16 (14.0) |
| T-cell depletion  |              |
| Yes               | 78 (68.4)    |
| No                | 36 (31.6)    |
| Prophylaxis for acute GVHD | |
| Cyclosporin-A based regimen | 22 (19.3) |
| Tacrolimus based regimen | 92 (80.7)   |

Values are presented as median (range) or number (%).

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; HCT-CI, hematopoietic cell transplantation-comorbidity index; HSCT, hematopoietic stem cell transplantation; CR, complete remission; GVHD, graft-versus-host disease.

Table 2. Outcomes of allogeneic hematopoietic stem cell transplantation

| Variable                                      | Value        |
|----------------------------------------------|--------------|
| Infused stem cell dose (CD<sub>34</sub> cell), /kg |              |
| < 6.0 x 10<sup>6</sup>                        | 62 (54.4)    |
| ≥ 6.0 x 10<sup>6</sup>                        | 52 (45.6)    |
| Engraftment (after HSCT day), /μL             |              |
| ANC > 500                                     | 11 (8–18)    |
| Platelet > 20,000                             | 11 (7–50)    |
| Acute GVHD                                    |              |
| No                                           | 46 (40.4)    |
| Grade I                                      | 30 (26.3)    |
| ≥ Grade II–IV                                | 38 (33.3)    |
| Chronic GVHD                                  |              |
| Yes                                          | 30 (26.3)    |
| No                                           | 84 (73.7)    |
| Viral reactivation                            |              |
| All                                          | 71 (62.3)    |
| CMV                                          | 67 (58.8)    |
| EBV                                          | 15 (13.2)    |
| Non-relapse mortality within 1 year          | 7 (6.1)      |
| Relapse                                      | 27 (23.7)    |
| Death, cause of death                         |              |
| All                                          | 45 (39.5)    |
| Relapse                                      | 19           |
| Acute and chronic GVHD                       | 14           |
| Infection                                    | 8            |
| Others                                       | 4            |

Values are presented as number (%) or median (range).

ANC, absolute neutrophil count; GVHD, graft-versus-host disease; CMV, cytomegalovirus; EBV, Epstein-Barr virus.

regimens were used for 82 patients (71.9%). Thirty patients (26.3%) had a matching sibling donor, and others had alternative donors including matched unrelated donors (n = 68, 59.7%) and haplo-identical related donors (n = 16, 14%). In vivo T-cell depletion was performed in 78 patients (68.4%; thymoglobulin in 71 patients and alemtuzumab in seven patients). Ninety-two patients (80.7%) received tacrolimus-based regimen to prevent acute GVHD.
Most patients (98.2%) showed successful engraftment of donor cells, except for two patients with engraftment failure. The cumulative incidence of overall acute GVHD and grade II to IV acute GVHD on day 100 was 59.6% and 33.3%, respectively. The chronic GVHD rate at 3 years was 26.3% (Table 2). Viral reactivation including cytomegalovirus (CMV) and/or Epstein-Barr virus was identified in 71 patients (62.3%).

Three and 5-year OS rates were 76% and 59.4%, respectively. The number of deaths and causes of mortality over the entire follow-up period are shown in Table 2. Relapse was the most frequent cause of death (n = 19). Other causes included acute and chronic GVHD (n = 14), infection (n = 8), engraftment failure (n = 2), and secondary cancers (n = 2).

Cox proportional hazards regression analysis was used to identify the impact of clinical variables on survival outcome. Disease status at the time of HSCT, risk stratification by HCT-CI, and chronic GVHD were significantly associated with survival outcome. Compared with CR status at HSCT, non-CR status at HSCT had a

| Variable                        | Overall survival |
|---------------------------------|------------------|
| CR                              | 0.034            |
| Non-CR                          | 2.54             |
| Risk stratification by HCT-CI   | 0.000            |
| Standard                        |                  |
| High                            | 2.04             |
| 1.62–5.36                      |                  |
| Donor type                      | 0.656            |
| Matched related donor           | 0.73             |
| Matched unrelated donor         | 0.38–1.44        |
| Haplo-identical donor           | 0.33–2.30        |
| Conditioning                    | 0.662            |
| Myeloablative                   | 1.16             |
| 0.60–2.25                      |                  |
| RIC/NST                         |                  |
| T-cell depletion                | 1.69             |
| 0.35–1.32                      |                  |
| Prophylaxis for acute GVHD      | 0.259            |
| With cyclosporin-A              | 0.38–1.44        |
| With tacrolimus                 | 0.33–2.30        |
| Grade II–IV acute GVHD          | 0.068            |
| No                              |                  |
| Yes                             | 1.74             |
| 0.96–3.14                      |                  |

A p values were calculated by Cox-proportional hazards regression analysis.

HR, hazard ratio; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CR, complete remission; HCT-CI, hematopoietic cell transplantation-comorbidity index; RIC/NST, reduced intensity conditioning/non-myeloablative stem transplantation; GVHD, graft-versus-host disease.

Outcomes of allogeneic hematopoietic stem cell transplantation

Most patients (98.2%) showed successful engraftment of donor cells, except for two patients with engraftment failure. The cumulative incidence of overall acute GVHD and grade II to IV acute GVHD on day 100 was 59.6% and 33.3%, respectively. The chronic GVHD rate at 3 years was 26.3% (Table 2). Viral reactivation including cytomegalovirus (CMV) and/or Epstein-Barr virus was identified in 71 patients (62.3%). Three and 5-year OS rates were 76% and 59.4%, respectively. The number of deaths and causes of mortality over the entire follow-up period are shown in Table 2. Relapse was the most frequent cause of death (n = 19). Other causes included acute and chronic GVHD (n = 14), infection (n = 8), engraftment failure (n = 2), and secondary cancers (n = 2).
negative effect on OS (hazard ratio [HR], 2.54; \( p = 0.034 \)). Moreover, high risk HCT-CI was associated with worse overall survival (HR, 2.94; \( p = 0.000 \)). Chronic GVHD had a positive effect on survival outcome (HR, 0.30; \( p = 0.006 \)), while moderate-to-severe acute GVHD (grade II to IV) tended to have a negative effect on overall survival without statistical significance (HR, 1.74; \( p = 0.068 \)) (Table 3).

**Clinical characteristics and immune recovery**

One hundred four patients were evaluated for immune function reconstitution of T-cell subsets and humoral immunity 100 days after allogeneic transplantation (Table 4). The recovery of CD3+ T-cell was in the reference range in 88 patients (77.2%), whereas CD4+ cells recovered to normal levels in only 30 patients (26.3%). The CD8+ cells were restored to normal levels in 85 patients (74.6%). Among 108 patients assessed for NK cell status, 97 (89.8%) showed the normal range of NK cells. The B-cell recovery was in the reference range in 68 patients (59.6%). The serum levels of immunoglobulin G, A, and M were normal in 105 (92.1%), 78 (68.4%), and 85 (74.6%) cases.

Table 5 presents the results of statistical analyses of the individual effects of clinical variables on T-cell immune reconstitution. Prevention of GVHD using a tacrolimus-based regimen and T-cell depletion with thymoglobulin or alemtuzumab were significantly associated with delayed immune reconstitution of T-cells. The analysis of T-cell subset recovery according to clinical characteristics is summarized in Table 6. The median values of CD3+ and CD4+ cell counts were significantly lower in patients who underwent T-cell depletion than in patients without T-cell depletion. While CD8+ cell counts tended to increase in patients progressing to chronic GVHD, a significant decrease was detected in patients with acute GVHD and acute grade 2 or higher GVHD requiring active treatment, including steroids. The number of CD3+ cells was significantly reduced in patients progressing to chronic GVHD, and CD4+ cell counts tended to decrease in patients with CMV reactivation. However, there was no difference in T-cell subsets according to the relapse of underlying disease.

The difference in clinical outcomes depended on the analysis of T-cell recovery to normal status (Table 7). No significant differences in overall acute GVHD or grade II to IV acute GVHD were found between the normal and abnormal groups of T-cell reconstitution (\( p = 0.798 \) and \( p = 0.826 \), respectively). However, the incidence of chronic GVHD was significantly increased in the group with normal recovery compared to the abnormal group (\( p = 0.01 \)). In addition, Epstein-Barr virus reactivation was more frequently detected in the abnormal group of T-cell subsets (\( p = 0.045 \)). All viral reactivation events including CMV appeared to be more frequent in the ab-

| Variable                        | Median (range) | No. (%) |
|---------------------------------|----------------|---------|
| **CD3 cell status**             |                |         |
| Normal                          | 1,242 (508–3,769) | 88 (77.2) |
| Abnormal                        | 462 (54–688)    | 20 (17.5) |
| Not done                        | -              | 6 (5.3)  |
| **CD4 cell status**             |                |         |
| Normal                          | 449 (381–650)  | 30 (26.3) |
| Abnormal                        | 301 (217–370)  | 78 (68.4) |
| Not done                        | -              | 6 (5.3)  |
| **CD8 cell status**             |                |         |
| Normal                          | 330 (184–504)  | 85 (74.6) |
| Abnormal                        | 117 (78–179)   | 22 (19.3) |
| Not done                        | -              | 7 (6.1)  |
| **Natural killer cell status**  |                |         |
| Normal                          | 172 (91–431)   | 97 (85.1) |
| Abnormal                        | 81 (69–89)     | 11 (9.6) |
| Not done                        | -              | 7 (6.1)  |
| **B-cell status**               |                |         |
| Normal                          | 172 (91–431)   | 68 (59.6) |
| Abnormal                        | 81 (69–89)     | 39 (34.2) |
| Not done                        | -              | 7 (6.1)  |
| **Immunoglobulin-G recovery**   |                |         |
| Normal                          | 1,384 (559–2,428) | 105 (92.1) |
| Abnormal                        | 206 (28–394)   | 2 (1.8)  |
| Not done                        | -              | 7 (6.1)  |
| **Immunoglobulin-A recovery**   |                |         |
| Normal                          | 158 (70–1,415) | 78 (68.4) |
| Abnormal                        | 56 (55–69)     | 29 (25.4) |
| Not done                        | -              | 7 (6.1)  |
| **Immunoglobulin-M recovery**   |                |         |
| Normal                          | 88 (23–567)    | 85 (74.6) |
| Abnormal                        | 36 (23–39)     | 22 (19.3) |
| Not done                        | -              | 7 (6.1)  |
Table 5. Clinical characteristics contributing to T-cell reconstitution

| Variable                        | Total (n = 104) | Normal (n = 39) | Abnormal (n = 65) | p value |
|---------------------------------|-----------------|-----------------|-------------------|---------|
| Age, yr                         |                 |                 |                   | 0.633   |
| < 40                            | 44 (42.3)       | 19 (48.7)       | 25 (38.5)         |         |
| 40–49                           | 25 (24.0)       | 10 (25.6)       | 15 (23.4)         |         |
| 50–59                           | 27 (26.0)       | 8 (20.5)        | 19 (29.2)         |         |
| ≥ 60                            | 8 (7.7)         | 2 (5.1)         | 6 (9.2)           |         |
| Sex                             |                 |                 |                   | 1.000   |
| Male                            | 54 (51.9)       | 20 (51.3)       | 34 (52.3)         |         |
| Female                          | 50 (48.1)       | 19 (48.7)       | 31 (47.7)         |         |
| Diagnosis                       |                 |                 |                   | 0.900   |
| AML                             | 53 (51.0)       | 19 (48.7)       | 34 (52.3)         |         |
| ALL                             | 23 (22.1)       | 10 (25.6)       | 13 (20.6)         |         |
| MDS                             | 11 (10.6)       | 3 (7.7)         | 8 (12.3)          |         |
| Lymphoma                        | 3 (2.9)         | 1 (2.6)         | 2 (3.1)           |         |
| Others                          | 14 (13.5)       | 6 (15.4)        | 8 (12.3)          |         |
| Disease status at transplanta   |                 |                 |                   | 0.381   |
| CR                              | 66 (63.5)       | 23 (59.0)       | 43 (66.2)         |         |
| Non-CR                          | 22 (21.2)       | 11 (28.2)       | 11 (16.9)         |         |
| Others                          | 16 (15.4)       | 5 (12.8)        | 11 (16.9)         |         |
| HCT-CI risk                     |                 |                 |                   | 0.165   |
| Standard                        | 61 (58.7)       | 19 (48.7)       | 42 (64.6)         |         |
| High                            | 43 (41.3)       | 20 (51.3)       | 23 (35.4)         |         |
| Conditioning intensity          |                 |                 |                   | 0.434   |
| MA                              | 74 (71.2)       | 30 (76.9)       | 44 (67.7)         |         |
| RIC/NST                         | 30 (28.8)       | 9 (23.1)        | 21 (32.3)         |         |
| Prevention of GVHD              |                 |                 |                   | 0.038   |
| With cyclosporin-A              | 20 (19.2)       | 12 (30.8)       | 8 (12.3)          |         |
| With tacrolimus                 | 84 (80.8)       | 27 (69.2)       | 57 (87.7)         |         |
| Donor type                      |                 |                 |                   | 0.31    |
| Matched related donor           | 26 (25.0)       | 11 (28.2)       | 15 (23.1)         |         |
| Matched unrelated donor         | 63 (60.6)       | 25 (64.1)       | 38 (58.5)         |         |
| Haplo-identical donor           | 15 (14.4)       | 3 (7.7)         | 12 (18.5)         |         |
| T-cell depletion                |                 |                 |                   | <0.001  |
| No                              | 29 (28.9)       | 20 (69.0)       | 9 (31.0)          |         |
| Yes                             | 75 (72.1)       | 19 (48.7)       | 56 (86.2)         |         |
| Infused CD34+ cells (> 6 × 10⁶/kg) | 58 (55.8)     | 19 (48.7)       | 39 (60.0)         | 0.359   |

Values are presented as number (%). A p values were calculated by chi-square test or Fisher’s exact test.
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CR, complete remission; HCT-CI, hematopoietic cell transplantation-comorbidity index; MA, myeloablative; RIC/NST, reduced intensity conditioning/non-myeloablative stem cell transplant; GVHD, graft-versus-host disease.

aNon-CR: refractory and relapse in acute leukemia, blast crisis in CML, Others, no information on disease status, all MDS patients.
normal group of T-cell subsets, but without statistical difference. Other variables were not significantly correlated with T-cell reconstitution. In the analysis of survival outcomes at 100 days after transplantation based on the recovery of T-cell subsets, the overall survival and relapse-free survival tended to be higher in patients with CD4+ cells recovering above 350/μL, no without any statistical significance (Fig. 1). The recovery of CD8+ cells had no effect on the survival outcomes. T-cell depletion had the biggest negative effect on T-cell immune reconstitution (odds ratio, 6.71; p < 0.001) based on multiple logistic regression analysis (Table 8).

No significant variable was found to affect the recovery of NK cells (Table 9). However, patients receiving greater than 6 × 10^6 CD34+ cells/kg more frequently reached the reference range than patients receiving fewer than 6 × 10^6 CD34+ cells/kg, with nearly statistical significance (p = 0.054). We did not find any impact of B-cell recovery status on clinical outcomes after transplantation.

**DISCUSSION**

The recovery of innate and adaptive immune systems occurs gradually during the post-transplantation period. The timing of immune reconstitution is affected by many variables during the transplantation, such as the source of stem cells, disparity of human leukocyte antigen and minor histocompatibility antigen, the conditioning regimen, graft manipulation, immune

| Table 6. Recovery of T-cell subsets according to clinical factors |
|---------------------------------------------------------------|
| Variable | CD3 cells | CD4 cells | CD8 cells |
|-------------------------|-----------|-----------|-----------|
| In vivo T-cell depletion |           |           |           |
| No TCD (n = 29) | 2,113 (152–3,769) | 334 (233–650) | 316 (108–504) |
| TCD (n = 75) | 1,082 (54–2,990) | 305 (217–543) | 301 (78–452) |
| p value | 0.002 | 0.011 | 0.741 |
| Acute GVHD |           |           |           |
| No | 1,176 (182–3,769) | 331 (233–650) | 337 (85–504) |
| Yes | 1,099 (54–2,060) | 313 (217–609) | 261 (78–459) |
| p value | 0.175 | 0.295 | 0.016 |
| Grade II–IV acute GVHD |           |           |           |
| No | 1,250 (280–3,769) | 326 (218–650) | 340 (85–504) |
| Yes | 1,117 (54–2,306) | 309 (217–621) | 273 (78–459) |
| p value | 0.216 | 0.295 | 0.034 |
| Chronic GVHD |           |           |           |
| No | 1,301 (182–3,769) | 330 (218–650) | 293 (78–456) |
| Yes | 1,005 (54–2,214) | 314 (217–529) | 344 (107–504) |
| p value | 0.029 | 0.295 | 0.110 |
| CMV reactivation |           |           |           |
| No | 1,173 (54–3,769) | 364 (227–650) | 306 (87–456) |
| Yes | 1,119 (58–3,317) | 305 (217–608) | 305 (78–504) |
| p value | 0.975 | 0.054 | 0.932 |
| Relapse |           |           |           |
| No | 1,168 (140–3,769) | 322 (218–650) | 309 (83–486) |
| Yes | 1,099 (54–3,095) | 311 (217–610) | 280 (78–504) |
| p value | 0.372 | 0.771 | 0.724 |

Values are presented as median (range). A p values were calculated by Mann-Whitney U test.
TCD, T-cell depletion; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
Table 7. Clinical outcomes according to T-cell reconstitution

| Variable                  | Total (n = 104) | Normal (n = 39) | Abnormal (n = 65) | p value |
|---------------------------|-----------------|-----------------|-------------------|---------|
| **GVHD**                  |                 |                 |                   |         |
| Acute GVHD                | 59 (56.7)       | 21 (53.8)       | 38 (58.5)         | 0.798   |
| Grade II–IV acute GVHD    | 32 (30.8)       | 13 (33.3)       | 19 (29.2)         | 0.826   |
| Chronic GVHD              | 27 (26.0)       | 16 (41.0)       | 11 (16.9)         | 0.010   |
| **Viral reactivation**    |                 |                 |                   |         |
| CMV                       | 61 (58.7)       | 19 (48.7)       | 42 (64.6)         | 0.165   |
| EBV                       | 15 (14.4)       | 2 (5.1)         | 13 (20.0)         | 0.045   |
| All viral reactivation    | 63 (61.2)       | 20 (51.3)       | 43 (67.2)         | 0.162   |
| **Survival outcome**      |                 |                 |                   |         |
| Relapse                   | 18 (17.3)       | 7 (17.9)        | 11 (16.9)         | 1.000   |
| NRM100                    | 6 (5.8)         | 3 (7.7)         | 3 (4.6)           | 0.828   |
| Death                     | 32 (30.8)       | 10 (25.6)       | 22 (33.8)         | 0.510   |
| Cause of death            |                 |                 |                   | 1.000   |
| GVHD                      | 84 (80.8)       | 32 (82.1)       | 52 (80.0)         |         |
| Infectious complication   | 20 (19.2)       | 7 (17.9)        | 13 (20.0)         |         |

Values are presented as number (%). A p values were calculated by chi-square test or Fisher’s exact test.

GVHD, graft-versus-host disease; CMV, cytomegalovirus; EBV, Epstein-Barr virus; NRM100, non-relapse mortality within 100 days after transplant.

Figure 1. Survival outcomes according to the T-cell subsets recovery at 100 days after allogeneic hematopoietic stem cell transplantation. (A, B) Overall survival. (C, D) Relapse free survival. A p values were calculated by log-rank test.
suppressive therapy (especially corticosteroids), and the presence of GVHD [1]. Given the complexity of the transplantation process, it is impossible to quantify the impact of any one of these factors on individual engraftment; all of these factors work in concert to regulate immune reconstitution.

The type of conditioning regimen affects immune recovery after transplantation, and varies depending on treatment intensity and the effect of immunosuppression. Fludarabine has been widely used in reduced intensity conditioning regimens in combination with other drugs, confirming the effect of strong immunosuppressive effect on donor cell engraftment and in reducing non-relapse mortality [10]. However, the effect of fludarabine on T-cells was attributed to increased relapse after transplantation, resulting in poor DFS, and the OS was not improved compared to other pretreatment regimens [11].

Since the recovery of immune function after transplantation is affected by a wide variety of clinical conditions, data pertaining to the recovery of each cell over time are scarce. In the case of peripheral blood stem cell transplantation, neutrophil recovery occurs at approximately 2 weeks. The recovery of NK cells occurs at 1 to 3 months and earlier than the recovery time of more than 1,000/μL CD4+ T-cells [5]. CD8+ T-cells recover faster than CD4+ T-cells but 100 days after transplantation. Similar results were obtained in this study (Table 6). The number of lymphocytes recovered up to 100 days after transplantation affects the transplantation outcome. In the present study, we found that the degree of recovery of CD4+ cells tended to affect the clinical outcomes. Therefore, early recovery of T-cells after transplant may have important clinical implications. The engraftment of neutrophils and platelets was achieved at a median of 11 days after transplant. NK cell counts were restored to the normal range in about 90% of patients by day 100 post-transplantation. Successful engraftment of neutrophils, platelets, and NK cells was obtained at similar times, as described previously.

In patients undergoing HSCT, the adaptive immune system is significantly impaired largely due to the loss of naïve T-cells and the reduced function of existing T-cells [12]. A functional thymus is essential to generate an effective T-cell repertoire following HSCT. However, thymus-dependent differentiation of T-cells, particularly in the case of CD4+ T-cells, is a critical hurdle in aging patients who commonly experience thymic atrophy [13]. The peripheral naïve T-cell receptor repertoire is never fully restored in older patients and infectious morbidity is directly related to low CD4+ T-cell counts [14]. Whereas CD8+ T-cells are predominantly derived by clonal expansion that occurs outside the thymus [15], CD8+ T-cell recovery is not affected by aging [16]. Within the first 100 days after HSCT, cellular immunodeficiency due to insufficient NK cells and T-cells increases the susceptibility of patients to viral reactivation including CMV and Epstein-Barr virus, as well as viral diseases [17,18].

In this study, T-cell subsets including CD3+ T-cells, CD4+ T-cells, and CD8+ T-cells returned to the reference range in about 40% of patients within 100 days after HSCT. Evaluating the risk of viral reactivation according to T-cell recovery status revealed that the risk of EBV reactivation was higher in the abnormal group than in the normal group. All viral reactivation events including CMV reactivation appeared to be more fre-

---

**Table 8. Multiple logistic regression analysis for T-cell reconstitution**

| Variable                  | Multiple logistic regression analysis | OR (95% CI) | p value |
|---------------------------|--------------------------------------|-------------|---------|
| T-cell depletion          |                                      | 6.71 (2.63–18.52) | < 0.001 |
| Acute GVHD                |                                      | 0.65 (0.31–1.34)  | 0.256   |
| Grade II–IV acute GVHD    |                                      | 0.96 (0.42–2.06)  | 0.866   |
| Chronic GVHD              |                                      | 1.41 (0.69–2.89)  | 0.343   |
| Relapse                   |                                      | 1.38 (0.48–3.07)  | 0.545   |
| Death                     |                                      | 1.42 (0.33–6.2)   | 0.641   |

OR, odds ratio; CI, confidence interval; GVHD, graft-versus-host disease.
Table 9. Clinical characteristics contributing to NK cell reconstitution

| Variable                        | Total (n = 108) | Normal (n = 97) | Abnormal (n = 11) | p value |
|---------------------------------|-----------------|-----------------|-------------------|---------|
| Age, yr                         |                 |                 |                   | 0.109   |
| < 40                            | 45 (41.7)       | 38 (39.2)       | 7 (63.6)          |         |
| 40–49                           | 26 (24.1)       | 23 (23.7)       | 3 (27.3)          |         |
| 50–59                           | 29 (26.9)       | 29 (29.9)       | 0                 |         |
| ≥ 60                            | 8 (7.4)         | 7 (7.2)         | 1 (9.1)           |         |
| Sex                             |                 |                 |                   | 0.846   |
| Male                            | 57 (52.8)       | 52 (53.6)       | 5 (45.5)          |         |
| Female                          | 51 (47.2)       | 45 (46.4)       | 6 (54.5)          |         |
| Diagnosis                       |                 |                 |                   | 0.727   |
| AML                             | 54 (50.0)       | 50 (51.5)       | 4 (36.4)          |         |
| ALL                             | 26 (24.1)       | 22 (22.7)       | 4 (36.4)          |         |
| MDS                             | 11 (10.2)       | 10 (10.3)       | 1 (9.1)           |         |
| Lymphoma                        | 3 (2.8)         | 3 (3.1)         | 0                 |         |
| Others                          | 14 (13.0)       | 12 (12.4)       | 2 (18.2)          |         |
| Disease status at transplantation*|                 |                 |                   | 0.294   |
| CR                              | 69 (63.9)       | 64 (66.0)       | 5 (45.5)          |         |
| Non-CR                          | 23 (21.3)       | 19 (19.6)       | 4 (36.4)          |         |
| Others                          | 16 (14.8)       | 14 (14.4)       | 2 (18.2)          |         |
| HCT-CI risk                     |                 |                 |                   | 0.520   |
| Standard                        | 63 (58.3)       | 58 (59.8)       | 5 (45.5)          |         |
| High                            | 45 (41.7)       | 39 (40.2)       | 6 (54.5)          |         |
| Conditioning intensity          |                 |                 |                   | 0.434   |
| MA                              | 77 (71.3)       | 70 (72.2)       | 7 (63.6)          |         |
| RIC/NST                         | 31 (28.7)       | 27 (27.8)       | 4 (36.4)          |         |
| Donor type                      |                 |                 |                   | 0.399   |
| Matched related donor           | 30 (27.8)       | 28 (28.9)       | 2 (18.2)          |         |
| Matched unrelated donor         | 63 (58.3)       | 57 (58.8)       | 6 (54.5)          |         |
| Haplo-identical donor           | 15 (13.9)       | 12 (12.4)       | 3 (27.3)          |         |
| T-cell depletion                |                 |                 |                   | 1.000   |
| No                              | 32 (29.0)       | 29 (28.4)       | 3 (27.3)          |         |
| Yes                             | 76 (71.7)       | 68 (71.6)       | 8 (72.7)          |         |
| Infused CD34⁺ cells (> 6 × 10⁶/kg) | 58 (53.7)     | 59 (60.8)       | 3 (27.2)          | 0.054   |
| Infused CD34⁺ cells (≤ 6 × 10⁶/kg) | 50 (46.3)     | 38 (39.2)       | 8 (72.7)          |         |

Values are presented as number (%). A p values were calculated by chi-square test or Fisher’s exact test.

NK, natural killer; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CR, complete remission; HCT-CI, hematopoietic cell transplantation-comorbidity index; MA, myeloablative; RIC/NST, reduced intensity conditioning/non-myeloablative stem cell transplant.

*Non-CR: refractory and relapse in acute leukemia, blast crisis in CML, Others, no information on disease status, all MDS patients.

quent in the abnormal group of T-cell subsets. The absolute number of CD4+ cells in patients with CMV reactivation was significantly lower than in patients without CMV reactivation. Therefore, viral reactivation might be
directly correlated with T-cell recovery status.

In addition, we assessed the impact of clinical variables on T-cell reconstitution. GVHD prophylaxis with the tacrolimus-based regimen and T-cell depletion before HSCT resulted in delayed immune reconstitution of T-cells. T-cell depletion was a serious adverse effect following T-cell recovery. Acute GVHD tended to negatively affect the recovery of T-cell subsets; however, no consistent results with statistical significance were observed. Clinical risk factors for immune reconstitution including the source of stem cells, degree of human leukocyte antigen disparity, and conditioning regimen were not significantly associated with delayed immune recovery in this study. The addition of fludarabine with greater immunosuppressive effects to conditioning regimen reduced the frequency of acute GVHD during the early period after transplantation, even though over two-thirds of donors were alternative donors. Since 2011, selectively targeted therapy including ruxolitinib, imatinib, or cell therapy has been used to actively treat acute GVHD patients. Further, decreased use of long-term or high-dose steroids, was observed. The incidence of chronic GVHD was higher in the normal group of T-cell subsets than in the abnormal group, which differed from a prior report that suggested possible immune dysfunction in patients who developed chronic GVHD after HSCT [19]. The difference might be related to the lower incidence of extensive chronic GVHD requiring systemic therapy including corticosteroids. However, the exact cause leading to the difference is unclear.

The humoral immune response is mediated by antibodies and requires both functional B- and T-cells. In addition to the delayed recovery of T-cells described above, a significantly impaired reconstitution was observed in cells of B-cell lineage following HCT [20]. After HSCT, the reconstitution of B-cell repertoire is often delayed because of complications associated with GVHD, age, and infections [21]. Normal B-cell counts are reached between 6 and 9 months after HSCT and after more than 12 months post-GVHD. Antibody production is also impaired after HSCT. Serum IgM levels return to normal usually within 3 to 6 months, whereas recovery of serum IgG levels may be delayed up to 1 year or longer. Impaired antibody immunity has been correlated with an increased risk of infections after HSCT primarily due to encapsulated bacteria [22]. In this study, about 60% of the patients achieved the normal range of B-cell counts and serum levels of immunoglobulin including IgG, IgM, and IgA 100 days after transplantation. B-cell recovery appeared to be faster than the reported incidence, even with GVHD and older age. No risk factor was associated with delayed B-cell reconstitution.

This study has several limitations. Major limitations were the participation of patients diagnosed with various hematologic diseases and the different types of transplantation using various donor types. Because the disease per se or the treatment process might be affected by the immune system, it may be difficult to obtain objective results due to a possible selection bias. Further, the small sample size prevented definitive conclusions. Therefore, classification of patients into uniform groups and further analysis based on groups was a difficult task. Finally, only absolute counts of lymphocyte subsets (CD3+ T-cells, CD4+ T-cells, CD8+ T-cells, and NK cells) were relatively simple and facilitated the evaluation of immune reconstitution. However, functional assessment tests such as T-cell repertoire and T-cell receptor expression were not performed.

In summary, there is a delayed immune reconstitution in patients undergoing allogeneic HSCT with tacrolimus-based GVHD prophylactic regimens, T-cell depletion, and possibly due to acute GVHD resulting in increased morbidity from viral reactivation. Treatment strategies to prevent infectious complications are needed to enhance immune reconstitution and recovery following allogeneic HSCT with fludarabine-based conditioning.

**KEY MESSAGE**

1. The immune recovery status post-allogeneic hematopoietic stem cell transplantation (HSCT) was affected by graft-versus-host disease (GVHD) prophylactic regimens, T-cell depletion, and possibly those manifesting acute GVHD.
2. Delayed immune reconstitution resulted in increased morbidity from viral reactivation.
3. Treatment strategies to prevent infectious complications are needed to enhance immune reconstitution following allogeneic HSCT with fludarabine-based conditioning.
Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
Statistical support services provided by the Department of Biostatistics Consulting of Soonchunhyang University Bucheon Hospital (M.S., Bora Lee) are gratefully acknowledged.

REFERENCES

1. Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol 2016;7:507.
2. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009;113:4114-4124.
3. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010;24:257-272.
4. Krenger W, Hollander GA. The immunopathology of thymic GVHD. Semin Immunopathol 2008;30:439-456.
5. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-3868.
6. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
7. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
8. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855-864.
9. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008;30:425-437.
10. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993;4:371-375.
11. Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013;31:701-709.
12. Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998;92:4464-4471.
13. Chaudhry MS, Velardi E, Malard F, van den Brink MR. Immune Reconstitution after allogeneic hematopoietic stem cell transplantation: time to T up the thymus. J Immunol 2017;198:40-46.
14. Palmer DB. The effect of age on thymic function. Front Immunol 2013;4:316.
15. Fagnoni FF, Lozza I, Zibera C, et al. T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology 2002;106:27-37.
16. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997;89:3700-3707.
17. Chatzidimitriou D, Gavriliak E, Sakellari I, Diza E. Hematopoietic cell transplantation and emerging viral infections. J Med Virol 2010;82:328-338.
18. Gennery AR, Maggina P. Infection following haematopoietic stem cell transplantation. Paediatr Child Health 2014;24:236-241.
19. Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol 2011;46:80-87.
20. Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant 2005;35 Suppl 1:S53-S57.
21. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996;2:44-53.
22. Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 2016;7:901-916.